<DOC>
	<DOC>NCT02322593</DOC>
	<brief_summary>The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.</brief_summary>
	<brief_title>Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Key Patients who are diagnosed as gastric cancer. No prior treatment for gastric cancer. Negative or unknown for HER2 testing. ECOG performance status of 0 or 1. Key Unmanageable diarrhea. Current peripheral sensory neuropathy or paresthesia. Pregnant or lactating female.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>First Line Treatment</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>